Cite
HARVARD Citation
Eriksson, J. et al. (2020). Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 inactivated varicella-zoster vaccine (ZVIN) trial. Expert review of pharmacoeconomics & outcomes research. pp. 613-621. [Online].